Atlas Trials

Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors

Clinical trial NCT06797362 · AVAILABLE

Trial details

NCT number
NCT06797362
Sponsor
Nuvalent Inc.
Status
AVAILABLE
Study type
EXPANDED_ACCESS
Non Small Cell Lung CancerROS1-positive Non-Small Cell Lung Cancer (NSCLC)

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.